Oric Pharmaceuticals, Inc. ORIC Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -42.6%-1.3pp | -41.3%-1.5pp | -39.7%+4.1pp | -43.8%+4.6pp | -48.5%+6.3pp | |
| Return on assets | -39.8%-1.9pp | -37.9%-1.0pp | -36.9%+3.7pp | -40.6%+4.1pp | -44.8%+3.8pp | |
| Return on invested capital | -55.9%-2.9pp | -53%-3.2pp | -49.9%+9.2pp | -59.1%+6.3pp | -65.4%+5.4pp | |
| Liquidity | ||||||
| Current ratio | 16.3×+2.2× | 14.1×-0.5× | 14.6×-1.5× | 16.1×+4.1× | 12×+1.4× | |
| Quick ratio | 16.3×+2.2× | 14.1×-0.5× | 14.6×-1.5× | 16.1×+4.1× | 12×+1.4× | |
| Cash ratio | 3.2×+0.9× | 2.2×-0.2× | 2.5×-1.7× | 4.2×+1.4× | 2.8×+0.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $3.94-10.0% | $4.38+6.5% | $4.11-0.8% | $4.15+34.1% | $3.09-11.3% | |
| Valuation | ||||||
| Market capitalization | $976.17M+23.4% | $796.64M-31.6% | $1.17B+30.4% | $893.94M+126% | $396.33M-30.4% | |
| Enterprise value | $923.07M+23.9% | $758.42M-32.2% | $1.12B+36.3% | $821.35M+135% | $350.21M-32.6% | |
| Price / book | 2.4×-1.3× | 2.1×-0.8× | 2.9×+0.1× | 2.8×+1.0× | 1.8×-0.5× | |
| Free cash flow yield | -11.4%+3.3pp | -14%-4.0pp | -10.1%+3.5pp | -13.6%+15.8pp | -29.4%-9.4pp | |
| Earnings yield | -13.8%+2.9pp | -16.3%-4.6pp | -11.6%+3.7pp | -15.4%+18.2pp | -33.5%-11.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Oric Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Oric Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.